Immunological and molecular variability of OspA and OspC. Implications for Borrelia vaccine development.
about
Epidemiology and diagnosis of Lyme borreliosisBiology of infection with Borrelia burgdorferiMolecular typing of Borrelia burgdorferi sensu lato: taxonomic, epidemiological, and clinical implicationsChronic or late lyme neuroborreliosis: analysis of evidence compared to chronic or late neurosyphilis.Acylated cholesteryl galactoside as a novel immunogenic motif in Borrelia burgdorferi sensu stricto.Identification and functional characterisation of Complement Regulator Acquiring Surface Protein-1 of serum resistant Borrelia garinii OspA serotype 4Borrelia burgdorferi stimulates the production of interleukin-10 in peripheral blood mononuclear cells from uninfected humans and rhesus monkeys.One-year duration of immunity induced by vaccination with a canine Lyme disease bacterin.Genetic analysis of Borrelia garinii OspA serotype 4 strains associated with neuroborreliosis: evidence for extensive genetic homogeneity.Evidence for vaccine synergy between Borrelia burgdorferi decorin binding protein A and outer surface protein A in the mouse model of lyme borreliosis.DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but Not for resolution of Lyme diseaseImpact of genotypic variation of Borrelia burgdorferi sensu stricto on kinetics of dissemination and severity of disease in C3H/HeJ mice.Arthropod-transmitted infectious diseases of cats.Approaches toward the directed design of a vaccine against Borrelia burgdorferi.Microbiological and serological diagnosis of Lyme borreliosis.Borrelia burgdorferi-induced tolerance as a model of persistence via immunosuppression.Vaccination with the ospA- and ospB-Negative Borrelia burgdorferi Strain 50772 Provides Significant Protection against Canine Lyme DiseaseThe role of Borrelia burgdorferi outer surface proteinsAn immune evasion mechanism for spirochetal persistence in Lyme borreliosis.Therapeutic passive vaccination against chronic Lyme disease in mice.Understanding barriers to Borrelia burgdorferi dissemination during infection using massively parallel sequencingBacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease.Acylated cholesteryl galactosides are specific antigens of borrelia causing lyme disease and frequently induce antibodies in late stages of disease.Assessment of transcriptional activity of Borrelia burgdorferi and host cytokine genes during early and late infection in a mouse modelConstruction and analysis of variants of a polyvalent Lyme disease vaccine: approaches for improving the immune response to chimeric vaccinogens.Identification of Borrelia burgdorferi ospC genotypes in canine tissue following tick infestation: implications for Lyme disease vaccine and diagnostic assay designAnalysis of antibody response in humans to the type A OspC loop 5 domain and assessment of the potential utility of the loop 5 epitope in Lyme disease vaccine developmentDetection and typing of Borrelia burgdorferi sensu lato in Ixodes ricinus ticks attached to human skin by PCR.Demonstration of OspC type diversity in invasive human lyme disease isolates and identification of previously uncharacterized epitopes that define the specificity of the OspC murine antibody response.Genetic structure of marine Borrelia garinii and population admixture with the terrestrial cycle of Lyme borreliosis.Infection history of the blood-meal host dictates pathogenic potential of the Lyme disease spirochete within the feeding tick vector.
P2860
Q22248045-63EB100C-DA19-4AC0-BD96-09D600A85B6EQ22252198-CC0B1D23-0CA8-4525-AFB4-2871D3EB28A8Q24550721-079E6616-D5B6-40BA-8D36-C425F06906D4Q30458971-957C9B48-4B4B-410C-9562-BE72F6C32BABQ30804250-A4C12A0A-30A8-4EC7-8679-AE3A6FE8C513Q33530563-F03A83B1-E284-41D2-BE5F-48C5ADB1A99FQ33754714-E0780339-4A2D-4FB4-BD09-6163A02A115AQ33825744-872BF2B1-A037-4A3E-9242-2978206B35A8Q33964187-E5529154-6B27-47B9-A849-B51FA3D71098Q34005057-EC03A042-C61D-4F11-A3B6-28980D07DB2FQ34006707-08827421-0FBA-4FDC-A35B-E48C7A750019Q34008219-15BC72D9-5BFC-4032-B2A8-86DD686AAE44Q34497985-E4EDD26B-A0F1-4240-9EC9-39568D661ADEQ34543900-3221598A-34F0-4B25-AD75-51C812E9B0EAQ34608068-23C36351-99AF-4348-8835-A1D0B828AB00Q35106547-2FE6972B-F161-4A22-BA28-2BC8B8113116Q35773884-D4A4D3FF-EF86-481C-A5C2-8060FC0996BEQ36179733-D4851170-3225-49DF-9099-D5195AAB5FD5Q36369900-E118E2F8-9654-4781-8F85-D264AE653255Q36821318-873CA239-8F61-4425-9EA1-90710CE30D8CQ36970890-736F117E-325E-4567-B687-2233158663DBQ37099227-3BA6ACDE-6861-4E6B-82C9-006F70173851Q37185250-01591A2D-0F2D-4054-8EE4-EA878D57330BQ37208398-0946E05A-2A43-445A-BBE9-BA3F3E9FCBBBQ37228833-39320927-65D5-4B2E-80D4-63D3D851D285Q37414209-FC5525A4-1CD1-43D1-B5A2-98C9B558086DQ38499117-CB38B322-8160-4561-A73A-BFBDB6BF5662Q39556224-43DEB44C-5DEB-4E96-BF4B-8B43A2DFC4EEQ40380026-BD749046-5B06-4361-B3F0-AD9085041A84Q51596377-27B127EC-5BF3-48EF-8E3B-F951A2C3F134Q52330933-E6BD17A7-D92B-45F8-A54D-60A5C7F938E7
P2860
Immunological and molecular variability of OspA and OspC. Implications for Borrelia vaccine development.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
Immunological and molecular va ...... Borrelia vaccine development.
@en
type
label
Immunological and molecular va ...... Borrelia vaccine development.
@en
prefLabel
Immunological and molecular va ...... Borrelia vaccine development.
@en
P2093
P356
P1433
P1476
Immunological and molecular va ...... Borrelia vaccine development.
@en
P2093
S Jauris-Heipke
V Preac Mursic
P2888
P304
P356
10.1007/BF01713341
P577
1996-03-01T00:00:00Z